参麦注射液联合CT引导下碘125粒子植入治疗非小细胞肺癌效果观察

Curative Effect of Shenmai Injection Combined with CT-guided Iodine 125 Particle Implantation in Treatment of Non-small Cell Lung Cancer

目的探讨参麦注射液联合碘125(125I)治疗中晚期非小细胞肺癌(NSCLC)的临床价值。方法选择2012年3月—2014年3月收治的NSCLC 94例,按治疗方案分为观察组和对照组,每组47例。对照组采用CT引导下放射性125I粒子植入治疗,观察组在对照组基础上联合参麦注射液。观察2组临床疗效,卡氏评分(KPS)、体重指数(BMI)改善情况及疾病进展时间(TTP),比较2组生存期和不良反应发生情况。结果观察组客观缓解率高于对照组(P<0.05)。2组治疗后KPS、BMI均较治疗前改善,且观察组改善情况优于对照组(P<0.05)。观察组TTP、中位生存时间长于对照组,1年生存率高于对照组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论参麦注射液联合125I粒子植入能有效提高中晚期NSCLC患者的疗效,延长患者生存时间,不良反应少。

Objective To investigate clinical value of Sbenmai injection combined with iodine 125 （125 I） in treatment of moderate-advanced non-small cell lung cancer （NSCLC）. Methods A total of 94 NSCLC patients admitted during March 2012 and March 2014 were divided into control group （n = 47） and observation group （n = 47） according to treatment plans. Control group received CT-guided radioactive particle 125I implantation, while observation group was added with Shenmai injection on the basis of the treatment for control group. Clinical efficacy, Karnofsky scores （KPS）, improvement of body mass index （BMI） and time to progress （TTP） were observed, survival rate and incidence rate of adverse reactions were compared in two groups. Results Objective remission rate in observation group was significantly higher than that in control group （P 〈 0.05）. After treatment, values of KPS and BMI were significantly improved compared with those before treatment in two groups, and the improvement in observation group was superior to that in control group （P 〈 0.05 ）. In observation group, TTP and median survival time were significantly longer, and 1 year survival rate was significantly higher than those in control group （P 〈 0. 05）. There was no significant difference in incidence rate of adverse reactions between two groups （P 〉 0.05）. Conclusion Shenmai injection combined with iodine （125 I） can effectively improve curative effect, prolong survival time with less adverse reactions in treatment of NSCLC patients.